Brintellix (Major Depressive Disorder) - Forecast and Market Analysis to 2023
|出版日期||內容資訊||英文 47 Pages
|Brintellix(重度憂鬱症)- 預測與市場分析 Brintellix (Major Depressive Disorder) - Forecast and Market Analysis to 2023|
|出版日期: 2014年05月30日||內容資訊: 英文 47 Pages||
Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded and competitive market, with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli Lilly's Cymbalta, and Otsuka/BMS's Abilify, along with the recent launch of the multimodal antidepressant, Lundbeck/Takeda's Brintellix, in January 2014, and the potential introduction of seven promising late-stage pipeline products into the market during the forecast period, from 2013 to 2023.
Brintellix (vortioxetine) is a multimodal antidepressant that is indicated for the treatment of MDD and was co-developed by Lundbeck and Takeda. It gained FDA approval in October 2013 and EMA approval in December 2013. Brintellix launched in the US market in January 2014 and its launch in European markets is expected during the second half of 2014 (Lundbeck, press release, December 27, 2013).